We are live on ! Find out more

24 hedge funds and large institutions have $6.73M invested in PAVmed in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

111% more capital invested

Capital invested by funds: $3.2M → $6.73M (+$3.54M)

60% more funds holding

Funds holding: 1524 (+9)

0.01% more ownership

Funds ownership: 0.01%0.02% (+0.01%)

Holders
24
Holders Change
+9
Holders Change %
+60%
% of All Funds
0.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
7
Reduced
2
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
-$20K -38 Closed
VFA
27
Valeo Financial Advisors
Indiana
-$5K -9 Closed

PAVM Hedge Fund Activity: Q1 2020 in Review

24 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q1 2020, worth a combined $6.73M — up 111% from $3.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PAVM positions and 3 closed out — a net gain of 10 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $791K. The largest seller was UBS Group, exiting entirely with an estimated $23K sold.

  • 24 institutional investors held PAVmed (PAVM) as of Q1 2020, up from 15 in Q4 2019.
  • Funds reported $6.73M of PAVmed stock for Q1 2020, up 111% quarter-over-quarter.
  • 13 funds opened new PAVmed positions in Q1 2020 and 3 closed out, a net change of +10 holders.
  • The largest PAVmed buyer in Q1 2020 was EAM Investors, an estimated $791K added.
  • The largest PAVmed seller in Q1 2020 was UBS Group, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2020.